Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
SAGE Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 21.15 |
| Open* | 21.29 |
| 1-Year Change* | -44.69% |
| Day's Range* | 20.36 - 21.29 |
| 52 wk Range | 16.52-59.99 |
| Average Volume (10 days) | 956.99K |
| Average Volume (3 months) | 32.86M |
| Market Cap | 1.25B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 59.88M |
| Revenue | 10.37M |
| EPS | -9.93 |
| Dividend (Yield %) | N/A |
| Beta | 1.13 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 27, 2023 | 21.15 | 0.61 | 2.97% | 20.54 | 21.28 | 20.49 |
| Sep 26, 2023 | 20.77 | 1.68 | 8.80% | 19.09 | 20.93 | 19.09 |
| Sep 25, 2023 | 19.20 | 0.03 | 0.16% | 19.17 | 19.53 | 19.09 |
| Sep 22, 2023 | 19.53 | 0.06 | 0.31% | 19.47 | 19.82 | 19.27 |
| Sep 21, 2023 | 19.55 | -0.03 | -0.15% | 19.58 | 19.69 | 19.17 |
| Sep 20, 2023 | 19.86 | -0.35 | -1.73% | 20.21 | 20.44 | 19.77 |
| Sep 19, 2023 | 20.38 | 0.12 | 0.59% | 20.26 | 20.61 | 19.96 |
| Sep 18, 2023 | 20.24 | -0.72 | -3.44% | 20.96 | 20.96 | 19.92 |
| Sep 15, 2023 | 20.95 | -0.39 | -1.83% | 21.34 | 21.53 | 20.48 |
| Sep 14, 2023 | 21.44 | -1.14 | -5.05% | 22.58 | 23.08 | 21.10 |
| Sep 13, 2023 | 22.58 | -0.79 | -3.38% | 23.37 | 23.80 | 22.40 |
| Sep 12, 2023 | 23.38 | 1.99 | 9.30% | 21.39 | 23.53 | 21.39 |
| Sep 11, 2023 | 21.60 | 0.14 | 0.65% | 21.46 | 22.12 | 21.30 |
| Sep 8, 2023 | 21.55 | 0.90 | 4.36% | 20.65 | 21.76 | 20.38 |
| Sep 7, 2023 | 20.77 | 0.39 | 1.91% | 20.38 | 21.04 | 20.12 |
| Sep 6, 2023 | 20.58 | 0.19 | 0.93% | 20.39 | 20.88 | 20.29 |
| Sep 5, 2023 | 20.49 | 0.50 | 2.50% | 19.99 | 20.61 | 19.56 |
| Sep 1, 2023 | 20.24 | 0.29 | 1.45% | 19.95 | 20.61 | 19.88 |
| Aug 31, 2023 | 19.96 | 0.40 | 2.04% | 19.56 | 20.38 | 19.56 |
| Aug 30, 2023 | 19.66 | -0.03 | -0.15% | 19.69 | 20.13 | 19.36 |
Sage Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2023 SAGE Therapeutics Inc Earnings Release Q3 2023 SAGE Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Wednesday, February 14, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 SAGE Therapeutics Inc Earnings Release Q4 2023 SAGE Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 7.686 | 6.308 | 1114.2 | 6.868 | 90.273 |
| Total Operating Expense | 554.675 | 467.217 | 517.974 | 714.992 | 483.511 |
| Selling/General/Admin. Expenses, Total | 227.699 | 183.498 | 196.952 | 345.777 | 201.404 |
| Research & Development | 326.163 | 283.166 | 292.714 | 368.815 | 282.107 |
| Operating Income | -546.989 | -460.909 | 596.226 | -708.124 | -393.238 |
| Interest Income (Expense), Net Non-Operating | 14.19 | 2.883 | 9.597 | 27.804 | 20.334 |
| Other, Net | 0.015 | 0.134 | 0.25 | 0.082 | 0.022 |
| Net Income Before Taxes | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Net Income After Taxes | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Net Income Before Extra. Items | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Net Income | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Income Available to Common Excl. Extra. Items | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Income Available to Common Incl. Extra. Items | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Diluted Net Income | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Diluted Weighted Average Shares | 59.3061 | 58.6702 | 53.0031 | 50.8338 | 46.1212 |
| Diluted EPS Excluding Extraordinary Items | -8.98363 | -7.8045 | 11.4347 | -13.3816 | -8.08483 |
| Diluted Normalized EPS | -8.98363 | -7.8045 | 11.9581 | -13.3816 | -8.08483 |
| Total Extraordinary Items | |||||
| Revenue | 7.686 | 6.308 | 1114.2 | 6.868 | 90.273 |
| Cost of Revenue, Total | 0.813 | 0.553 | 0.565 | 0.4 | |
| Gross Profit | 6.873 | 5.755 | 1113.64 | 6.468 | |
| Unusual Expense (Income) | 0 | 0 | 27.743 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 2.474 | 3.294 | 2.865 | 1.739 | 1.501 |
| Revenue | 2.474 | 3.294 | 2.865 | 1.739 | 1.501 |
| Cost of Revenue, Total | 0.205 | 0.23 | 0.143 | 0.184 | 0.2 |
| Gross Profit | 2.269 | 3.064 | 2.722 | 1.555 | 1.301 |
| Total Operating Expense | 172.931 | 158.764 | 156.767 | 143.219 | 129.908 |
| Selling/General/Admin. Expenses, Total | 75.565 | 65.708 | 67.329 | 61.482 | 52.411 |
| Research & Development | 97.161 | 92.826 | 89.295 | 81.553 | 77.297 |
| Operating Income | -170.457 | -155.47 | -153.902 | -141.48 | -128.407 |
| Interest Income (Expense), Net Non-Operating | 10.173 | 8.83 | 6.793 | 4.127 | 2.102 |
| Other, Net | -0.041 | -0.188 | -0.037 | 0.03 | 0.045 |
| Net Income Before Taxes | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Net Income After Taxes | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Net Income Before Extra. Items | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Net Income | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Income Available to Common Excl. Extra. Items | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Income Available to Common Incl. Extra. Items | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Diluted Net Income | -160.325 | -146.828 | -147.146 | -137.323 | -126.26 |
| Diluted Weighted Average Shares | 59.7696 | 59.6741 | 59.4967 | 59.4281 | 59.2663 |
| Diluted EPS Excluding Extraordinary Items | -2.68238 | -2.4605 | -2.47318 | -2.31074 | -2.13038 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -2.68238 | -2.4605 | -2.47318 | -2.31074 | -2.13038 |
| Unusual Expense (Income) | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 1336.98 | 1800.64 | 2122.37 | 1035.09 | 944.695 |
| Cash and Short Term Investments | 1272.49 | 1742.3 | 2099.55 | 1008.39 | 922.776 |
| Cash & Equivalents | 162.7 | 294.233 | 1661.08 | 126.705 | 190.943 |
| Short Term Investments | 1109.79 | 1448.06 | 438.467 | 881.688 | 731.833 |
| Prepaid Expenses | 50.826 | 39.841 | 22.821 | 26.7 | 21.919 |
| Total Assets | 1356.45 | 1825.29 | 2159.25 | 1084.15 | 952.705 |
| Property/Plant/Equipment, Total - Net | 13.43 | 19.125 | 31.819 | 42.897 | 5.643 |
| Property/Plant/Equipment, Total - Gross | 19.525 | 24.098 | 38.907 | 47.396 | 7.859 |
| Accumulated Depreciation, Total | -6.095 | -4.973 | -7.088 | -4.499 | -2.216 |
| Other Long Term Assets, Total | 6.039 | 5.52 | 5.057 | 6.16 | 2.367 |
| Total Current Liabilities | 99.259 | 85.193 | 67.204 | 112.128 | 86.03 |
| Accounts Payable | 18.95 | 10.45 | 3.691 | 15.266 | 34.036 |
| Accrued Expenses | 37.572 | 26.703 | 23.931 | 33.202 | 19.875 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 42.737 | 48.04 | 39.582 | 63.66 | 32.119 |
| Total Liabilities | 103.85 | 96.257 | 86.912 | 139.495 | 89.734 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 4.591 | 11.064 | 19.708 | 27.367 | 3.704 |
| Total Equity | 1252.6 | 1729.03 | 2072.33 | 944.655 | 862.971 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.006 | 0.006 | 0.006 | 0.005 | 0.005 |
| Additional Paid-In Capital | 3291.37 | 3227.47 | 3109.81 | 2587.32 | 1827.02 |
| Retained Earnings (Accumulated Deficit) | -2028.17 | -1495.39 | -1037.49 | -1643.57 | -963.329 |
| Treasury Stock - Common | -0.4 | -0.4 | -0.4 | -0.4 | -0.211 |
| Other Equity, Total | -10.206 | -2.66 | 0.415 | 1.295 | -0.515 |
| Total Liabilities & Shareholders’ Equity | 1356.45 | 1825.29 | 2159.25 | 1084.15 | 952.705 |
| Total Common Shares Outstanding | 59.5091 | 58.937 | 58.3084 | 51.8772 | 46.8883 |
| Total Receivables, Net | 13.66 | 18.506 | |||
| Accounts Receivable - Trade, Net | 13.66 | 18.506 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 1203.44 | 1336.98 | 1465.1 | 1578.88 | 1682.24 |
| Cash and Short Term Investments | 1129.58 | 1272.49 | 1393.64 | 1513.71 | 1625.24 |
| Cash & Equivalents | 206.557 | 162.7 | 199.826 | 206.51 | 178.674 |
| Short Term Investments | 923.028 | 1109.79 | 1193.81 | 1307.2 | 1446.57 |
| Total Receivables, Net | 15.002 | 13.66 | 18.448 | 23.722 | 19.797 |
| Accounts Receivable - Trade, Net | 15.002 | 13.66 | 18.448 | 23.722 | 19.797 |
| Prepaid Expenses | 58.85 | 50.826 | 53.017 | 41.455 | 37.206 |
| Total Assets | 1220.69 | 1356.45 | 1486.07 | 1601.38 | 1705.7 |
| Property/Plant/Equipment, Total - Net | 11.725 | 13.43 | 14.791 | 16.317 | 17.599 |
| Property/Plant/Equipment, Total - Gross | 19.525 | 22.847 | |||
| Accumulated Depreciation, Total | -6.095 | -5.248 | |||
| Other Long Term Assets, Total | 5.524 | 6.039 | 6.178 | 6.176 | 5.86 |
| Total Current Liabilities | 84.692 | 99.259 | 99.687 | 89.241 | 77.703 |
| Accounts Payable | 12.263 | 18.95 | 7.077 | 5.41 | 7.129 |
| Accrued Expenses | 18.369 | 37.572 | 28.299 | 22.77 | 15.434 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 54.06 | 42.737 | 64.311 | 61.061 | 55.14 |
| Total Liabilities | 87.557 | 103.85 | 105.951 | 97.141 | 87.201 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 2.865 | 4.591 | 6.264 | 7.9 | 9.498 |
| Total Equity | 1133.13 | 1252.6 | 1380.12 | 1504.24 | 1618.5 |
| Redeemable Preferred Stock | 0 | 0 | 0 | ||
| Common Stock | 0.006 | 0.006 | 0.006 | 0.006 | 0.006 |
| Additional Paid-In Capital | 3313.61 | 3291.37 | 3276.42 | 3262.2 | 3247.54 |
| Retained Earnings (Accumulated Deficit) | -2175 | -2028.17 | -1881.02 | -1743.7 | -1617.44 |
| Treasury Stock - Common | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 |
| Other Equity, Total | -5.088 | -10.206 | -14.883 | -13.872 | -11.201 |
| Total Liabilities & Shareholders’ Equity | 1220.69 | 1356.45 | 1486.07 | 1601.38 | 1705.7 |
| Total Common Shares Outstanding | 59.762 | 59.5091 | 59.4937 | 59.3887 | 59.0662 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 |
| Cash From Operating Activities | -460.036 | -378.182 | 664.28 | -528.706 | -260.671 |
| Cash From Operating Activities | 1.122 | 4.182 | 2.63 | 2.283 | 1.143 |
| Non-Cash Items | 65.955 | 94.034 | 95.306 | 142.591 | 91.856 |
| Changes in Working Capital | 5.671 | -18.506 | -39.729 | 6.658 | 19.212 |
| Cash From Investing Activities | 325.433 | -1002.45 | 442.684 | -143.156 | -512.461 |
| Capital Expenditures | -0.937 | -0.372 | -0.345 | -5.751 | -2.86 |
| Other Investing Cash Flow Items, Total | 326.37 | -1002.08 | 443.029 | -137.405 | -509.601 |
| Cash From Financing Activities | 3.07 | 13.334 | 426.762 | 607.624 | 659.358 |
| Financing Cash Flow Items | -0.043 | -1.385 | -2.503 | -1.244 | |
| Issuance (Retirement) of Stock, Net | 3.113 | 14.719 | 426.762 | 610.127 | 660.602 |
| Net Change in Cash | -131.533 | -1367.3 | 1533.73 | -64.238 | -113.774 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -146.828 | -532.784 | -385.638 | -248.315 | -122.055 |
| Cash From Operating Activities | -153.682 | -460.036 | -333.104 | -214.239 | -107.8 |
| Cash From Operating Activities | 0.323 | 1.122 | 0.832 | 0.554 | 0.275 |
| Non-Cash Items | 16.83 | 65.955 | 52.076 | 37.849 | 20.897 |
| Changes in Working Capital | -24.007 | 5.671 | -0.374 | -4.327 | -6.917 |
| Cash From Investing Activities | 194.867 | 325.433 | 235.656 | 124.704 | -9.558 |
| Other Investing Cash Flow Items, Total | 195.092 | 326.37 | 236.311 | 124.995 | -9.389 |
| Cash From Financing Activities | 2.672 | 3.07 | 3.041 | 1.812 | 1.799 |
| Issuance (Retirement) of Stock, Net | 3.301 | 3.113 | 3.08 | 1.836 | 1.799 |
| Net Change in Cash | 43.857 | -131.533 | -94.407 | -87.723 | -115.559 |
| Capital Expenditures | -0.225 | -0.937 | -0.655 | -0.291 | -0.169 |
| Financing Cash Flow Items | -0.629 | -0.043 | -0.039 | -0.024 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 14.6778 | 8789617 | 1706204 | 2023-06-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 10.6266 | 6363630 | 649207 | 2023-06-30 | LOW |
| Biogen Inc | Corporation | 10.4226 | 6241473 | 0 | 2023-03-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.3815 | 5019202 | 53550 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.9624 | 3570538 | -11550 | 2023-06-30 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 5.2007 | 3114375 | 24375 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.8393 | 2299140 | -435233 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.866 | 1716268 | 61568 | 2023-06-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 1.857 | 1112064 | 291861 | 2023-06-30 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 1.8269 | 1094000 | 0 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7827 | 1067545 | 27300 | 2023-06-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.7505 | 1048295 | -829697 | 2023-06-30 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 1.6699 | 1000000 | 300000 | 2023-06-30 | LOW |
| Palo Alto Investors LP | Hedge Fund | 1.4353 | 859517 | 0 | 2023-06-30 | LOW |
| Lord, Abbett & Co. LLC | Investment Advisor | 1.382 | 827577 | 637244 | 2023-06-30 | MED |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 1.3335 | 798548 | -613381 | 2023-06-30 | HIGH |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.0796 | 646495 | -228289 | 2023-06-30 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.0001 | 598918 | 592380 | 2023-06-30 | LOW |
| Manulife Investment Management (North America) Limited | Investment Advisor | 0.9918 | 593938 | -30733 | 2023-06-30 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.864 | 517402 | 26317 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com